Asset
CDX-3379
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03254927 | phase2 | terminated | 2018-03-27 | 2020-09-16 | Celldex Therapeutics | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma |
FDA applications (0)
This company has no applications containing this asset.